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ABSTRACT 
 
Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease is a 
life-threatening complication following hematopoietic stem cell transplantation. A 
quantitative polymerase chain reaction to evaluate EBV-genome copy numbers 
based on a nested polymerase chain reaction and an end-point dilution was used. 
Applying this assay EBV load was prospectively screened weekly in 123 patients 
after transplantation. The results demonstrate that EBV reactivations with more than 
1,000 EBV-genome copies measured in 105 peripheral blood mononuclear cells were 
observed in 31 patients (25.2%). Three patients developed lymphoproliferative 
disease with extremely high EBV-genome copies in peripheral blood mononuclear 
cells (>100,000 copies/105 cells) and plasma. After combined antiviral and immune 
therapy two of three patients showed a dramatic decrease of EBV load and survived, 
while the third patient died of lymphoma. A subclinical EBV reactivation was ob-
served in 24 cases (19.5%) with EBV-genome copies in 105 peripheral blood 
mononuclear cells ranging between 2,500 and mostly 10,000. After reduction of 
immunosuppression the EBV levels normalized. In four patients, the high copy 
number of ≥80,000 copies/105 peripheral blood mononuclear cells and plasma 
positivity prompted us to start pre-emptive therapy with rituximab and cidofovir for 
prevention of lymphoproliferative disease. After drug administration the high EBV 
load was reduced remarkably. Ninety-two patients (74.8%) who had ≤1,000 
copies/105 peripheral blood mononuclear cells did not develop EBV-associated 
lymphoproliferative disease. In conclusion, monitoring of EBV load is a sensitive and 
useful parameter in the surveillance of EBV reactivation for early intervention in EBV-
associated lymphoproliferative disease as well as for follow-up of the efficacy of 
therapy. 
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Introduction 
 
The Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis and 
has been found in association with several human malignancies [for review, see 
Andersson, 2000; Young and Rickinson, 2004]. Tumors classically linked with EBV 
are the Burkitt´s lymphoma [Burkitt, 1958; Epstein et al., 1964] and the nasopharyn-
geal carcinoma [zur Hausen et al., 1970]. However, EBV was also found to be in-
volved in the development of other neoplasias, such as B-cell lymphomas in immuno-
compromised transplant [Hopwood and Crawford, 2000] and AIDS patients [Hamil-
ton-Dutoit et al., 1991; Shibata et al., 1993], certain T-cell lymphomas [Jones et al., 
1988; Su et al., 1991; Meijer et al., 1996], Hodgkin´s lymphomas [Staal et al., 1989; 
Herbst et al., 1990; Niedobitek, 1996] and gastric carcinomas [Leoncini et al., 1993; 
Fukayama et al., 1994; Osato and Imai, 1996].  
Patients receiving immunosuppressive therapy after organ and hematopoietic stem 
cell transplantation run a particularly high risk of developing EBV-associated post-
transplant lymphoproliferative disease, which may take a rapid fatal course. Because 
of the growing number of high-risk transplantations the incidence of post-transplant 
lymphoproliferative disease is increasing. Several authors summarized the current 
knowledge of EBV-induced post-transplant lymphoproliferative disease with regard to 
the varying incidence, risk factors, heterogeneous clinical presentation, histological 
findings and treatment modalities [reviews: Purtilo et al., 1992; Savage and Waxman, 
1997; Lucas et al., 1997; Paya et al., 1999; Wagner et al., 2002a; Cohen, 2003; 
Loren et al., 2003; Meerbach et al., 2004]. Post-transplant lymphoproliferative 
disease can differ clinically from a mononucleosis-like syndrome to malignant 
lymphoma. The incidence varies between 0.5 and 20% depending on several risk 
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factors, particularly donor-recipient human leukocyte antigen mismatch, T-cell 
depletion of donor graft or use of antithymocyte globulin. Despite different treatment 
modalities including reduction of immunosuppression, conventional chemotherapy, 
administration of antiviral drugs such as aciclovir, ganciclovir, foscarnet, and cidofovir 
or hyperimmune globulin and interferon-α, adoptive immunotherapy with donor 
lymphocytes or EBV-specific cytotoxic T lymphocytes as well as the use of anti-B cell 
monoclonal antibodies the mortality rate is still high. Therefore, prevention of EBV-
associated post-transplant lymphoproliferative disease will be the main goal. To 
make this approach practical and successful, two points are important. First, it is 
necessary to identify “high-risk” patients. And secondly, sensitive and reliable 
methods have to be available for detecting EBV reactivation and early onset of post-
transplant lymphoproliferative disease. 
Serologic data, frequently used to diagnose viral infections, represent only indirect 
markers of infection and are often unreliable in immunocompromised patients. Quali-
tative polymerase chain reaction assays are unable to distinguish between active and 
latent infection. As reviewed by Rowe et al. [2001] quantitative polymerase chain 
reaction of EBV DNA in peripheral blood is a highly sensitive and specific method for 
monitoring transplanted patients. 
The present study was aimed at monitoring EBV load in plasma and peripheral blood 
mononuclear cells in 123 patients undergoing hematopoietic stem cell transplan-
tation. 
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PATIENTS, MATERIAL AND METHODS 
 
Patients 
In the prospective follow-up study of EBV load, 123 patients were included who 
underwent hematopoietic stem cell transplantation in the Department of Pediatrics at 
the University Jena between January 2000 and August 2006. Children who died 
within the first 8 weeks after stem cell transplantation because of underlying disease 
or other non-EBV-associated complications were not included in the study. 
Hematopoietic stem cell transplantation was performed because of hematological di-
seases in 70 patients, oncological diseases in 38 patients, rheumatological diseases 
in 8 patients and genetic diseases in 7 children. Eighty-three patients received an 
allogeneic stem cell transplantation from an unrelated donor (51 patients) and from a 
related donor (32 patients), respectively. Forty patients were treated by autologous 
stem cell transplantation. Thirteen patients underwent two or more transplantations. 
The patient group consisted of 48 female and 75 male patients with a median age of 
12 years (range: 0.2-25 years). The EBV serostatus of all patients was evaluated 
before transplantation. EBV load in plasma and peripheral blood mononuclear cells 
was prospectively monitored once weekly. If there were no signs of EBV reactivation 
until day +100, monitoring was continued monthly up to one year after stem cell 
transplantation. 
 
Clinical Samples and Controls 
Patient samples  
A total of 1,393 plasma samples, 2,827 samples of peripheral blood mononuclear 
cells, 14 samples of cerebrospinal fluid and 18 tissue samples were investigated by 
polymerase chain reaction. EDTA-blood (5 ml) was used for plasma extraction and 
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isolation of peripheral blood mononuclear cells. Blood samples were purified by 
Ficoll-Hypaque density gradients using Leucosep tubes (Greiner) for 15 min at 800g. 
Plasma was removed and repeated cleared by centrifugation for 20 min at 300g. The 
layer of mononuclear cells was carefully aspirated, washed three times with 
phosphate-buffered saline and sedimented by centrifugation at 250g for 10 min. The 
cell pellet was resuspended in 200 µl phosphate-buffered saline and cells were 
counted using a Neubauer chamber. Occasionally, 200 µl of native cerebrospinal 
fluid or up to 25 mg tissue were used for DNA extraction.  
 
Controls 
The EBV-genome negative cell line Ramos as well as an EBV p23 plasmid served as 
controls. The plasmid standard was generated as described recently by Krumbholz et 
al. [2006]. 
 
DNA Extraction 
DNA was extracted from plasma, peripheral blood mononuclear cells, cerebrospinal 
fluid and the EBV-negative control cell line Ramos by QIAamp DNA Blood Mini Kit 
(Qiagen). For tissue DNA isolation the  QIAamp DNA Mini Kit (Qiagen) was used. 
DNA was extracted according to the manufacturer’s instructions and DNA concen-
tration was determined by UV spectrometry. 
 
Quantitative EBV DNA analysis 
The method was described in detail previously [Meerbach et al., 2001]. The following 
steps were performed: 
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Preparation of dilution rows for samples and control standard 
For detection of EBV-genome copies by polymerase chain reaction 5 µl of DNA from 
plasma or cerebrospinal fluid as well as DNA from peripheral blood mononuclear 
cells was used in concentrations of 1 µg, 500 ng and 100 ng.  In case of positive 
polymerase chain reaction signal a dilution row was prepared by the factor 2 to at 
least 1:128 (plasma, cerebrospinal fluid) and 1 ng (peripheral blood mononuclear 
cells), respectively. From EBV plasmid DNA serial 10-fold dilutions were prepared 
from 108 to 10-1 copies/5 µl. 
 
Polymerase chain reaction 
The polymerase chain reaction for detecting the EBV sequences was performed 
using primers of the virus capsid antigen p23 region. The primer pair p23-1, p23-2 
was used to amplify a 482 base pairs fragment of the BLRF2 gene of EBV [Reischl et 
al., 1996]. The sequences are as follows: p23-1: 5´ATCAGAAATTTGCACTTT 
CTTTGC3´, p23-2: 5´CAGCTCCACGCAAAGTCAGATTG3´. For the detection of 
EBV-specific polymerase chain reaction products a set of internal primers (p23-3, 
p23-4) was used for nested PCR which amplifies a 363 base pairs segment. They 
have the following sequences: p23-3: 5´TTGACATGAGCATGGAAGAC3´, p23-4: 
5´CTCGTGGTCGTGTTCCCTCAC3´. A total volume of 50 µl reaction mixture 
consisted of polymerase chain reaction buffer (50 mM KCl, 1.5 mM MgCl2, 10 mM 
Tris-HCl at pH 8.3), 200 µM dNTP, 1 µM of each primer, 0.6 units Taq DNA 
polymerase (Roche), and 5 µl of DNA solution. After an initial denaturation step for 5 
min at 94°C, 30 cycles were performed each including 45 sec at 94°C for dena-
turation, 45 sec at 60°C for annealing, and 1.5 min at 72°C for extension, followed by 
an additional 7 min extension at 72°C. For the nested polymerase chain reaction, 1 µl 
of the polymerase chain reaction product from the first series of amplifications was 
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added to 49 µl of the polymerase chain reaction reaction mixture and amplified in 
additional 30 cycles. 
 
Agarose gel electrophoresis of viral DNA 
 A 10 µl sample of the amplification product was run on a 0.8% agarose gel 
electrophoresis. DNA was monitored under UV light after staining with ethidium 
bromide. The last visible band in each dilution row corresponds to about 10 viral 
copies (Figure 1). 
 
Interpretation 
To calculate the number of EBV copies in the initial DNA sample (1 µg of cell DNA or 
20 µl of plasma or cerebrospinal fluid, respectively) the dilution factor was multiplied 
by 10 (sensitivity level of polymerase chain reaction: approximately 10 EBV-genome 
copies). For plasma and cerebrospinal fluid, the result was multiplied by 50 to obtain 
copies per ml. For peripheral blood mononuclear cells, the calculation is based on 
the presumption that 1 µg total DNA represents approximately 105 cells [Knecht et 
al., 1992]. Polymerase chain reaction-positive plasma/cerebrospinal fluid samples 
and/or EBV-genome copy numbers >1,000 in 105 peripheral blood mononuclear cells 
were estimated as active EBV infection. 
 
Flow cytometry 
Percentage of lymphocytes was calculated by flow scan analysis with the Coulter 
Epics XL-MCL instrument (Coulter/Beckman). Monoclonal antibodies produced by 
Dako were used according to the manufacturer’s instructions. B lymphocytes were 
detected by anti-CD19+/CD22+ and anti-CD19+/CD22- antibodies. An anti-CD3+ 
antibody served for the detection of T cells. Suppressor/cytotoxic T cells and helper T 
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cells were counted by application of anti-CD8+/CD3+ and anti-CD4+/CD3+ antibodies, 
respectively. 
 
Antibody detection 
Patients sera were tested for antibodies to structural antigens (virus capsid antigen) 
and for antibodies to the early antigen complex of EBV by immunofluorescence  
according to the method described by Henle and Henle [1966]. In addition, antibodies 
to the recombinant protein Epstein-Barr nuclear antigen 1 rp72 were detected by 
ELISA (Biotest).  
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RESULTS 
 
EBV DNA load monitoring after hematopoietic stem cell transplantation 
EBV reactivations and primary infections, respectively with >1,000 EBV genome 
copies in 105 peripheral blood mononuclear cells were observed in 31 out of 123 
patients (25.2%) between days 19 and 303 (median day: 51) after stem cell trans-
plantation. The increase of EBV-genome copies was found at least two weeks before 
reactivation from undetectable concentrations in peripheral blood mononuclear cells 
via low copy numbers (10-100 copies/105 peripheral blood mononuclear cells) to 
intermediate values (≤1,000 copies/105 peripheral blood mononuclear cells) up to 
reactivation with >1,000 EBV-genome copies/105 peripheral blood mononuclear cells. 
Only one of the 31 patients (patient 64) with >1,000 EBV genome copies in 105 peri-
pheral blood mononuclear cells was EBV-seronegative before transplantation 
suggesting a primary infection. From 31 patients developing an active EBV infection 
26 (83.9%) had been treated with antithymocyte globulin. In 8 patients demonstrating 
elevated EBV levels T cell depletion in the transplant was performed by positive se-
lection of CD34+ progenitor cells. Characteristics of the patients with EBV reactivation 
are summarized in Table 1. Statistical calculations of cut-off values for EBV lympho-
proliferative disease as well as reactivation are shown in Table 2 and 3, respectively. 
Three patients (2.4%) developed an EBV-associated post-transplant lympho-
proliferative disease with extremely high EBV copy numbers in plasma and peri-
pheral blood mononuclear cells. In these patients, anti-EBV antibodies could be 
detected before transplantation. Thus, development of lymphoma was due to EBV 
reactivation. A strong increase of EBV-genome copies was observed 1-4 weeks 
before the onset of clinical signs. The high EBV load in plasma and peripheral blood 
mononuclear cells reduced dramatically after therapy in two cases, while the third 
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patient died of lymphoma. The decrease of EBV-genome copies was associated with 
a decrease of B lymphocytes and an increase of CD3+, CD8+/CD3+ and CD4+/CD3+ 
T lymphocytes. In the following the three cases of EBV-associated post-transplant 
lymphoproliferative disease are reported in detail: 
 
Patient 3 
A 11-year-old girl with chronic myeloid leukemia underwent allogeneic stem cell 
transplantation from an unrelated donor. For prophylaxis of graft-versus-host-
disease, she was given antithymocyte globulin, cyclosporine A and methotrexate. 
Ninety days after transplantation, she presented with fever, exsudative tonsillitis and 
lymph node swelling. A lymph node biopsy revealed an immunoblastic lymphoma 
positive for the proliferation marker Ki67 as well as for the CD20 antigen. By in situ 
hybridization EBV-encoded RNA (EBER) could be detected in the tumor cells. On 
day 81 after stem cell transplantation, she was found to have an extremely high EBV 
load (1.0 x 106 EBV-genome copies/105 peripheral blood mononuclear cells). The 
EBV-genome copies still increased to 13 x 106/105 peripheral blood mononuclear 
cells and 510,000/ml plasma on day +100. Also in the lymph node high EBV values 
were measured (13 x 106 copies/µg DNA). Despite of stop of immunosuppressive 
drugs and therapy with ganciclovir and foscavir, administration of anti-CD20 
monoclonal antibody rituximab and donor lymphocyte infusions, the general condition 
deteriorated remarkably. Pulmonary insufficiency required artificial respiration. After 
progressive insufficiency of circulation, renal and liver failure she died of multiorgan 
failure on day 111 after stem cell transplantation. 
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Patient 8 
A 12-year-old boy with acute lymphoblastic leukemia received an allogeneic stem cell 
transplantation from an unrelated donor. To prevent graft-versus-host-disease, he 
was given antithymocyte globulin, cyclosporine A and methotrexate. On day 66 after 
stem cell transplantation, he developed fever, inguinal and cervical lymphadenopathy 
and angina lacunaris. Histological examination revealed an immunoblastic B cell 
lymphoma. Tumor cells were positive for Ki67 and CD20 antigens as well as EBV-
encoded RNA (EBER). The active EBV infection could be confirmed by polymerase 
chain reaction detecting 4,000 EBV-genome copies/ml plasma, 500 copies/ml cere-
brospinal fluid and 16,000 copies/105 peripheral blood mononuclear cells. A B cell 
peak was seen on day +71 with 9.5% corresponding to 32 lymphocytes/µl. The 
antiviral and immune therapy consisted of withdrawal of cyclosporine A, continuation 
of ganciclovir and addition of cidofovir, rituximab and donor lymphocyte infusions. On 
day +73 the patient developed an acute pulmonary insufficiency managed by high-
dose O2 administration and methylprednisolone. The increasing EBV load (Figure 
2A) reached highest values on day +82 (16,000 copies/ml plasma; 300,000 
copies/105 peripheral blood mononuclear cells) and +84 (Figure 1). The boy pre-
sented still with fever, reduced general condition, diffuse changing pain, sickness, 
vomiting and fatigue. On day +88, for the first time T cells could be detected by flow 
cytometry increasing up to 17% CD3+ lymphocytes (Figure 2B) corresponding to 349 
cells/µl on day +92. CD8+/CD3+ T cell number increased to 14.5% (Figure 2B) 
corresponding to 411 cells/µl on day +95. A clinical worsening occurred with som-
nolence, confusion and central apnea. EBV polymerase chain reaction revealed 
1,000 copies/ml cerebrospinal fluid. The patient was additionally treated with dexa-
methasone and aminophylline. On day 114 after stem cell transplantation the boy 
developed an acute graft-versus-host-disease of skin, liver and intestine, which could 
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be successfully treated with methylprednisolone, cycosporine A, mycophenolate mo-
fetil and antithymocyte globulin. Clinical signs of graft-versus-host-disease occurred 
in line with rising numbers of CD3+ and CD8+/CD3+ T lymphocytes. The therapy of 
the post-transplant lymphoproliferative disease resulted in improvement of his 
general condition, resolution of fever, involution of lymphadenopathy and angina 
lacunaris. EBV-genome copies in plasma and peripheral blood mononuclear cells 
decreased remarkably to undetectable levels on day +119 (Figure 2A). 
 
Patient 21 
A 16-year-old boy with systemic lupus erythematodes received an autologous stem 
cell transplantation. On day +41 his general condition deteriorated with fever, sore 
throat and difficulty in swallowing. An ulcerative tonsillitis, cervical lymph node 
swelling and septical temperatures occurred 50 days after transplantation. The 
histological examination of lymph node biopsy revealed a non-Hodgkin lymphoma of 
high-grade malignancy with EBV-encoded RNA (EBER) detection as well as ex-
pression of the ZEBRA protein. First antiviral therapy consisted of aciclovir and 
ganciclovir. Because of further increasing EBV load (Figure 3A) with the highest 
values on day +55 (2,000 copies/ml plasma; 1.7 x 106 copies/105 peripheral blood 
mononuclear cells) the antiviral therapy was changed to cidofovir in combination with 
rituximab. In the following days the EBV load reduced dramatically (Figure 3A). In 
Figure 3B the elevated B cell counts are demonstrated showing a peak on day +54 
with 73.1% corresponding to 2,778 B cells/µl. The decline of EBV-genome copies 
and B cells was accompanied with a reconstitution of T cell immunity. T cells 
increased from 3% on day +55 to 27% CD3+ T cells corresponding to 1,291 cells/µl 
and 28% CD8+/CD3+ lymphocytes corresponding to 1,330 cells/µl on day +59, 
respectively (Figure 3B). From day +59 the patient became afebrile and gradually 
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improved. With complete recovery of clinical signs EBV-genome copies reached 
normal values (<10 copies/105 peripheral blood mononuclear cells). 
 
In four patients, the rapidly increasing EBV load to at least 80,000 EBV-genome 
copies/105 peripheral blood mononuclear cells together with EBV plasma positivity 
was the reason to start pre-emptive therapy with a single dose of rituximab (375 
mg/m2) and cidofovir (5 mg/kg/week for 2 weeks) for prevention of an EBV-asso-
ciated post-transplant lymphoproliferative disease. According to the increasing EBV 
load there was also an increase of B lymphocytes, reaching the highest value of 
17.4% on day +49 in patient 22 corresponding to 230 B cells/µl (Figure 4). After 
administration of rituximab the high EBV load of patients 20, 22, 23 and 95 in plasma 
(maximum: 250,000; 1,000; 2,000; 1,000 copies/ml, respectively) and peripheral 
blood mononuclear cells (maximum: 80,000; 600,000; 80,000; 80,000 copies/105 
peripheral blood mononuclear cells, respectively) decreased remarkably accom-
panied by a reduction of B lymphocytes. 
A subclinical EBV reactivation was observed in 24 patients (19.5%) with EBV-
genome copies mostly between 2,500 and 10,000/105 peripheral blood mononuclear 
cells. Only 5 of the 24 patients had a single higher peak of 20,000 or 40,000 
copies/105 peripheral blood mononuclear cells. After reduction or stop of immuno-
suppression the EBV levels normalized. 
The 92 patients (74.8%) who had copy numbers of ≤1,000 copies/105 peripheral 
blood mononuclear cells did not develop EBV-associated post-transplant lympho-
proliferative disease. 
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EBV serostatus 
From the 123 patients undergoing stem cell transplantation 13 children were EBV 
seronegative before transplantation (10.6%). For protection they were given immuno-
globulins after transplantation resulting in high IgG antibody titers against virus 
capsid antigen and nuclear antigen of EBV. 
 17 
DISCUSSION 
 
One increasing area of concern is EBV infection and its relevance to post-transplant 
lymphoproliferative diseases. Post-transplant lymphoproliferative diseases encom-
pass a spectrum of lymphoid proliferations to lymphomas that occur in recipients of 
solid organ and bone marrow or peripheral blood stem cell transplants in connection 
with immunosuppression. The development of a life-threatening EBV-associated 
post-transplant lymphoproliferative disease is a serious complication after transplan-
tation. The availability of potentially effective therapeutic regimens for EBV post-
transplant lymphoproliferative disease increased the necessity for early identification 
of the subset of patients at high risk of developing this complication. Therapeutic 
efforts will probably be most effective if they are introduced early in the course of this 
rapidly progressing disease and before the onset of overt clinical symptoms.  
The aim of the performed prospective study in 123 patients undergoing hemato-
poietic stem cell transplantation was the monitoring of EBV load for early detection of 
EBV reactivation. The results indicate that EBV reactivations are frequent events 
after stem cell transplantation as described by van Esser et al. [2001a]. About 25% 
of our patients showed EBV reactivation at a median time of 51 days after stem cell 
transplantation. According to Dominietto et al. [2004] EBV reactivation is high (above 
50%) in patients undergoing an alternative donor transplant and occurs at a median 
interval of 45 days from stem cell transplantation. Whereas modulation of immuno-
suppression was sufficient in 24 out of our 31 patients to normalize EBV levels, four 
patients received pre-emptive therapy with rituximab and cidofovir to prevent post-
transplant lymphoproliferative disease. However, three patients (2.4%) developed 
post-transplant lymphoproliferative disease, of whom one died of lymphoma. By com-
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bined antiviral and immune therapy two patients with post-transplant lympho-
proliferative disease could be successfully treated.  
Concerning the diagnosis of EBV reactivation many studies demonstrated that the 
quantitative EBV DNA detection correlates with EBV-caused immunopathologic 
changes in the development of EBV post-transplant lymphoproliferative disease 
[Kenagy et al., 1995; Martinez et al., 1995; Bai et al., 1997; Rowe et al., 1997; 
Brengel-Pesce et al., 2002; Gärtner et al., 2002; Sirvent-von Bueltzingsloewen et al., 
2002]. High amounts of EBV in peripheral blood mononuclear cells were detected in 
these patients [Savoie et al., 1994; Rooney et al., 1995; Lucas et al., 1998]. Several 
authors have reported a significantly increased EBV load at the time of diagnosis of 
post-transplant lymphoproliferative disease, up to 4log10 higher than in control groups 
[Bai et al., 1997; Riddler et al., 1994; Rowe et al., 1997; Meerbach et al., 2001]. A 
rapid increase in peripheral blood EBV DNA load diagnosed and predicted post-
transplant lymphoproliferative disease [Stevens et al., 2001a; Van Esser et al., 
2001a; Orentas et al., 2003].  
In addition, quantitative polymerase chain reaction assay for EBV DNA in peripheral 
blood is useful in monitoring the efficacy of therapy [Hoshino et al., 2000; Meerbach 
et al., 2001; Gärtner et al., 2002]. Kenagy et al. [1995] diagnosed markedly elevated 
levels of EBV DNA in post-transplant lymphoproliferative disease during illness as 
well EBV DNA levels were reduced dramatically due to effective therapy. This 
observation is in line with our data. The EBV load of two patients with post-transplant 
lymphoproliferative disease increased within 4-5 weeks to maximal values of up to 
1.7 million copies in 105 peripheral blood mononuclear cells. After combined antiviral 
and immune therapy the EBV load decreased rapidly to undetectable concentrations. 
However, despite of different therapeutic measures patient 3 died of lymphoma. She 
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presented distinct higher copy numbers and showed already with the first clinical 
symptoms 1.0 million EBV-genome copies. The copy numbers rose to 13 million and 
did not decrease during therapy. The high viral load appears to be a poor prognostic 
sign. 
Curtis et al. [1999] analyzed in a long-term multi-center study incidence, risk factors 
and outcome of post-transplant lymphoproliferative disease. The risk for early-onset 
post-transplant lymphoproliferative disease, e.g. during the first year after 
transplantation, was strongly associated with (i) unrelated or human leukocyte anti-
gen mismatched related donor, (ii) T-cell depletion of donor marrow, (iii) use of anti-
thymocyte globulin or anti-lymphocyte globulin, and (iv) anti-CD3 monoclonal 
antibody (OKT3) for prophylaxis or treatment of acute graft-versus-host-disease. 
Additionally to these four main risk factors a weaker association could be 
demonstrated with the occurrence of graft-versus-host-disease grades II to IV and 
with conditioning regimens that included irradiation. Of epidemiological importance is 
the synergistic occurrence of several risk factors. So, the rate of post-transplant 
lymphoproliferative disease among patients with no risk factor was 0.5% increasing 
to 1.7% in the case of one risk factor. The rate reached 8% in the presence of two 
risk factors and increased to the highest rate of diseases of more than 20% with at 
least three major risk factors [Curtis et al., 1999]. An increased risk of post-transplant 
lymphoproliferative disease with more than one risk factor showed also the three 
patients with post-transplant lymphoproliferative disease in the presented study. All of 
them were treated with antithymocyte globulin as a main risk factor. Additionally, two 
of these patients were irradiated as part of the conditioning regimen. One of the EBV-
seropositive patients developed a post-transplant lymphoproliferative disease after a 
T cell depleted CD34+ selected autologous stem cell transplantation for systemic 
lupus erythematodes. Although the risk of EBV post-transplant lymphoproliferative 
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disease after autologous transplantation is low, case reports of this complication in 
the autologous setting exist [Chao et al., 1993, Briz et al., 1997, Hauke et al., 1998]. 
Recently, Powell and coworkers [2004] observed an unexpected high incidence of 
EBV lymphoproliferative diseases after CD34+ selected autologous stem cell trans-
plant in neuroblastoma. The authors concluded that the combination of tandem stem 
cell transplantation and CD34+ selection may have increased immunosuppression in 
these patients to a point where there is an elevated risk of EBV lymphoproliferative 
disease. Nash et al. [2003] reported EBV-associated lymphoproliferative diseases in 
patients after autologous stem cell transplantation for the control of severe auto-
immune diseases. The addition of antithymocyte globulin in the high-dose immuno-
suppressive therapy regimen in these patients as well as in our case report and 
CD34+ selection of the autologous graft may induce a higher degree of immuno-
suppression with an increased risk of transplant-related complications including EBV 
lymphoproliferative disease. 
Concerning the time point, the incidence of post-transplant lymphoproliferative 
disease was highest 1 to 5 months after transplantation with a peak in the third 
month [Curtis et al., 1999]. In several studies the median time from stem cell trans-
plantation to diagnosis lymphoproliferative disease was 76 days [Simon et al., 1991], 
71.5 days [Micallef et al., 1998] and 86 days [Gross et al., 1999], respectively. Accor-
ding to these data, in the presented study first clinical signs of post-transplant 
lymphoproliferative disease occurred on days +50, +66, and +90, respectively. Early-
onset forms often show a rapid disease progression with a median survival of 0.6 
months [Gross et al., 1999]. Micallef et al. [1998] described in 5 out of 8 patients a 
fulminant course with multiorgan failure and death within 3-8 days after onset of 
clinical signs. An incidence of 1.2% of fatal lymphoproliferative disease after allo-
geneic bone marrow transplantation was observed by Simon et al. [1991] with a 
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course rapidly progressive leading to death in 2-5 weeks. Such a fulminant course of 
post-transplant lymphoproliferative disease was also observed in patient 3, who died 
on day 21 after onset of clinical symptoms.  
A disadvantage at present is that EBV polymerase chain reaction is not yet 
standardized. This is why published data differ in method, sensitivity, material and 
even in the copy numbers of the results discussed in the following paragraphs:  
Method: Looking at the method EBV load can be detected by semiquantitative [Lukas 
et al., 1998], quantitative competitive [Rowe et al., 1997; Baldanti et al., 2000; Yang 
et al., 2000; Gärtner et al., 2002] or real-time polymerase chain reaction [Hoshino et., 
2000; Wagner et al., 2002b; Orentas et al., 2003; Yancoski et al., 2004]. In the pre-
sented prospective study, the author’s used a semiquantitative nested EBV poly-
merase chain reaction [Meerbach et al., 2001], which clearly detects 10 viral copies 
in 105 peripheral blood mononuclear cells. As reported recently [Krumbholz et al., 
2006], a comparison of the semiquantitative nested EBV polymerase chain reaction 
to a LightCycler-based polymerase chain reaction resulted in a good correlation 
between both methods as demonstrated for standard plasmid DNA, reference DNA 
isolated from the EBV-genome containing Namalwa cell line, and DNA extracted 
from plasma/cerebrospinal fluid. However, a decrease of sensitivity by factor 10-100 
was found in the LightCycler assay for DNA derived from peripheral blood mono-
nuclear cells when larger amounts of background DNA were used presuming an in-
hibitory effect of cellular DNA. This was not observed in the nested EBV polymerase 
chain reaction. In order to be able to detect low copy numbers (10-100 EBV-genome 
copies/105 peripheral blood mononuclear cells) for better watching increasing EBV-
genome copies screening of viral load  in peripheral blood mononuclear cells is done 
in our laboratory by nested EBV polymerase chain reaction. 
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Material: Concerning the sample matrix testing of plasma, whole blood, leukocyte or 
mononuclear cell fractions are possible. Peripheral blood mononuclear cells are a 
useful material for measurement EBV load in transplant patients [Hoshino et al., 
2001, Orentas et al., 2003]. However, whole blood combines all blood compartments 
that may harbor EBV [Stevens et  al., 2001b]. Hakim et al. [2007] have found com-
parable sensitivities and a close quantitative correlation between EBV load in whole 
blood and peripheral blood mononuclear cells suggesting that a normalization to cell 
number in cellular specimens may not be necessary. Plasma as material for EBV 
polymerase chain reaction is favored by several authors [Orii et al., 2000, Niesters et  
al., 2000, Wagner et al., 2001]. In comparison to mononuclear cells the specificity for 
the diagnosis of EBV lymphoproliferative disease seems to be higher if plasma is 
taken for analysis as underlined by Wagner et al. [2001]. In contrast, the study 
performed by Hakim et al. [2007] demonstrated that whole blood and peripheral 
blood mononuclear cells are more sensitive than plasma alone when assayed for 
EBV load. In our experience, an increase in EBV-genome copies occurs earlier in 
peripheral blood mononuclear cells than in plasma and not all patients with EBV 
reactivation had positive plasma polymerase chain reaction results. Plasma poly-
merase chain reaction turned to be positive days to weeks later in patients with post-
transplant lymphoproliferative disease, while copy numbers in peripheral blood 
mononuclear cells much earlier increased to >1,000 copies/105 peripheral blood 
mononuclear cells suggesting EBV reactivation. But plasma polymerase chain 
reaction might be of importance in the surveillance of therapy. Van Esser et al. 
[2001b] used the quantitative monitoring of EBV DNA levels in plasma for the 
prediction of the response to therapy of EBV post-transplant lymphoproliferative 
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disease after stem cell transplantation. Orii et al. [2000] concluded that antiviral 
therapy should be continued until qualitative plasma DNA is shown to be negative.  
Cut-off: In the literature, the cut-off levels for the risk of post-transplant lymphopro-
liferative disease development vary considerably, e.g. between 200 copies/105 
peripheral blood mononuclear cells [Green et al., 1999], ≥300/105 peripheral blood 
mononuclear cells [Cesaro et al., 2004], >300/µg DNA [Sirvent-von Bueltzingsloewen 
et al., 2002], >102,5/µg DNA [Hoshino et al., 2001], >500/75,000 peripheral blood 
mononuclear cells [Frias et al., 2001], >1,000/105 cells [Bacigalupo, 2005], 
>4,000/µg DNA [Wagner et al., 2004], 6,215/ml blood [Yancoski et al., 2004] and 
10,000/µg DNA [Orentas et al., 2003]. As shown in Table 2, EBV load of >100,000 
EBV-genome copies /105 peripheral blood mononuclear cells significantly predicts 
EBV lymphoproliferative disease in our study, whereas patients with ≤1,000 EBV-ge-
nome copies/105 peripheral blood mononuclear cells did not develop a lymphopro-
liferative disorder. The cut-off value of >1,000 EBV-genome copies in 105 peripheral 
blood mononuclear cells for the interpretation of EBV reactivation bases on our own 
experimental data with a lot of samples and was empirically stated. As depicted in 
Table 3, if an amount of viral load of >1,000 EBV-genome copies/105 peripheral 
blood mononuclear cells was taken for diagnosis EBV reactivation, sensitivity and 
specificity of this value was 100%, predictive values of positive and negative results 
was 1.00. If plasma was analyzed and a viral load of ≥500 EBV-genome copies/ml 
was used for the interpretation of active EBV infection, specificity reached 100% and 
predictive values for positive and negative results were 1,00. However, sensitivity 
yielded only 48.4% suggesting that screening of EBV load only in plasma is not 
sensitive enough for early intervention to prevent lymphoproliferative disease. 
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In the search for additional markers for predicting post-transplant lymphoproliferative 
disease, the determination of anti-EBV-specific T cell response as well as B lympho-
cytes should be taken into account. The results of several studies suggest that, in the 
future, the virus load measurement might be assisted by monitoring the EBV-specific 
immune response [Meij et al., 2003, Clave et al., 2004, Annels et al., 2006]. The 
authors measured the anti-EBV-specific T cell response in correlation to EBV load 
and the occurrence of EBV reactivation and lymphoproliferation, respectively in 
patients after allogeneic stem cell transplantation. Failure to detect EBV-specific 
CD8+ T cells in patients with high-level reactivation was associated with the sub-
sequent development of EBV post-transplant lymphoproliferative disease [Meij et al., 
2003]. Controlling of EBV reactivation was characterized by rapid EBV-specific T 
lymphocyte increase concomitant to decreasing viral load [Clave et al., 2004].  Com-
parable to this observation two patients with post-transplant lymphoproliferative di-
sease in the presented study showed after successful therapy a remarkable de-
crease of viral load accompanied with a complete recovery of clinical signs and an 
increase of total T cells, cytotoxic and helper T lymphocytes. The determination of 
specific circulating B lymphocyte population by flow cytometry is advocated as an 
additional predictive marker for development of post-transplant lymphoproliferative 
disease. The significant increase in B cell counts in patients with post-transplant lym-
phoproliferative disease presumably results from EBV-induced B cell proliferation 
[Levasseur et al., 2003]. Likewise, in patients 8 and 21 as well as in patient 22 with a 
lymphoproliferative disease of the presented study a B cell peak could be measured. 
Serial CD19+ B lymphocyte measurements may also serve as a marker for clinical 
response during the treatment of post-transplant lymphoproliferative disease with the 
anti-B cell monoclonal antibody rituximab. Several studies have shown, that the treat-
ment of post-transplant lymphoproliferative disease with rituximab resulted in reso-
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lution of lymphoma. Clinical remission was accompanied by B cell depletion in the 
peripheral blood [McGuirk et al., 1999; Kuehnle et al., 2000; Ansell et al., 2002; Ver-
schuuren et al., 2002;  Levasseur et al., 2003] . Our own data confirm these obser-
vations. Two out of three patients with lymphoproliferative disease could be success-
fully treated with rituximab as part of the therapy occurring along with a decrease of B 
lymphocytes. 
Regarding the therapeutic measures for prevention of EBV lymphoproliferative di-
sease, modulation of immunosuppression based on EBV load is the first-line treat-
ment. This resulted in a normalization of EBV levels in 24 out of 31 patients in the 
presented study. However, rapidly increasing EBV-genome copies in peripheral 
blood mononuclear cells together with EBV viremia call for pre-emptive therapy. It 
should consist of a combined treatment including reduction of immunosuppression, 
administration of antiviral drugs and immunotherapeutic agents, like cidofovir plus 
rituximab. Pre-emptive therapy with a single dose of rituximab led to the prevention of 
post-transplant lymphoproliferative disease and was first done by van Esser et al. 
[2002] and confirmed by Gruhn et al. [2003] and Dominietto et al. [2004]. The ad-
ministration of rituximab induced a dramatic decrease of EBV-genome copies in 
peripheral blood mononuclear cells and plasma and effective depletion of B lympho-
cytes [Gruhn et al., 2003]. Rituximab was given to four patients of the presented 
study in combination with the antiviral agent cidofovir. Antivirals may have positive 
effects by inhibiting the lytic replication due to the suppression of proteins of the lytic 
cycle supporting the maintenance of lymphoproliferation [Montone et al. 1996]. In 
addition, detection of EBV DNA in plasma may indicate EBV viremia with the release 
of infectious virions. Inhibition of lytic virus production could inhibit the new-infection 
of B lymphocytes. 
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As underlined by Bacigalupo [2005] and confirmed in our own study, EBV reactiva-
tion is a very frequent event especially in patients undergoing alternative donor he-
matopoietic stem cell transplantation with antithymocyte globulin in the conditioning 
regimen. For this reason, patients should be monitored weekly by quantitative 
polymerase chain reaction because viral load is a significant predictor of post-trans-
plant lymphoproliferative disease. Prevention of EBV lymphoproliferative disease by 
pre-emptive therapy based on molecular monitoring of EBV load is an attractive 
option to decrease the occurrence of post-transplant lymphoproliferative disease.
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Table 1: Clinical and laboratory data of patients with EBV reactivation after hematopoietic stem cell transplantation 
 
 
Pa- Age Sex  Diag-  Conditioning regimen         Transplant  EBV reactivation 
tient  (years)   nosis       donor  stem cell day     highest copy number per 
             source      105 PBMCs / ml plasma 
___________________________________________________________________________________________________________ 
Patients with post-transplant lymphoproliferative disease 
3 11 female CML  FTBI, CY, ATG   MUD  S  + 81  1.3 x 107 / 510,000 
8 12 male  ALL  FTBI, VP, TH, ATG   MUD  S  + 63  300,000 / 250,000 
21 16 male  SLE  CY, FLU, PRED, ATG  A  S: CD34+ + 45  1.7 x 106 / 2,000 
 
Patients receiving pre-emptive therapy 
20 14 female MDS  BU, CY, MEL, ATG   MRD  S: CD34+ + 38  80,000 / 250,000 
22 1 male  MDS  BU, CY, MEL, ATG   MUD  S: CD34+ + 39  600,000 / 1,000 
23 9 female JCA  CY, FLU, PRED, ATG  A  S: CD34+ + 36  80,000 / 2,000 
95 19 male  GCT  (CIS, VP, IFO)   A  (S, B)    -    - 
(BU, CY, FLU, TH, ATG) MUD S  + 33  80,000 / 1,000 
   
Patients with subclinical EBV reactivation 
43 12 female MDS  FLU, TH, ATG   MUD  B  + 49  10,000 
45 3 female ALL  FTBI, VP, ATG   MMUD B  + 97  5,000 
52 12 female CML  FTBI, CY, ATG   MUD  S: CD34+ + 75  10,000 
53 20 female SLE  CY, FLU, PRED, ATG  A  S: CD34+ + 25  10,000 
64 1 male  NBL  CBPT, VP, MEL   A  S: CD34+ + 303  2,500 
75 5 male  JMML  (BU, CY, MEL, ATG)  MUD  B      -        - 
ARA C    MUD S  + 49 2,500 
76 17 female ALL  FTBI, VP, ATG   MUD  B  + 147  5,000 
81 15 male  SAA  CY, ATG    MRD  B  + 41  2,500 
82 12 male  ALL  FTBI, CY, ATG   MUD  S  + 46  2,500 
84 17 male  AML  FTBI, CY, MEL, ATG  MUD  S  + 104  2,500 
88 20 male  ALL  FTBI, VP, ATG   MUD  B  + 51  10,000 
Table 1: continuation 
 
 
Pa- Age Sex  Diag-  Conditioning regimen         Transplant  EBV reactivation 
tient  (years)   nosis       donor  stem cell day     highest copy number per 
             source      105 PBMCs / ml plasma 
__________________________________________________________________________________________________________ 
89 6 female ALL  FTBI, VP    MRD  C  + 252  2,500 
97 8 male  AML  BU, CY, MEL   MRD  B  + 63  2,500 / 1,000 
98 22 female ALL  FTBI, VP, ATG   MUD  B  + 41  10,000 / 2,000 
101 3 male  NBL  CBPT, VP, MEL   A  S: CD34+ + 19  40,000 
102 13 female CML  FTBI, CY, ATG   MMUD S  + 42  20,000 / 1,000 
106 2 male  AML  BU, CY, MEL, ATG   MMUD B  + 87  40,000 
107 6 male  NHL  FTBI, VP, TH, ATG   MMUD B  + 55  5,000 / 500 
108 4 male  BT  (CBPT, VP, MTX)   A  S      -           -   
      (CY, TH)    A  S  + 21 40,000 
112 6 male  ALL  FTBI, VP, ATG   MUD  B  + 27  40,000 / 8,000 
115 17 male  MDS  BU, CY, MEL, ATG   MUD  B  + 58  10,000 / 1,000 
117 8 female ALL  FTBI, VP, ATG   MUD  B  + 62  2,500 / 1,000 
118 13 female ALL  FTBI, VP, ATG   MUD  B  + 55  20,000 / 500 
120 12 male  ALL  FTBI, VP, ATG   MUD  B  + 152  2,500 
___________________________________________________________________________________________________________ 
EBV: Epstein-Barr virus PBMCs: peripheral blood mononuclear cells  
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BT: brain tumor, CML: chronic myeloid leukemia, JCA: juvenile chronic arthritis, 
JMML: juvenile myelomonocytic leukemia, GCT: germ cell tumor, MDS: myelodysplastic syndrome, NBL: neuroblastoma, NHL: non-Hodgkin 
lymphoma, SAA: severe aplastic anemia, SLE: systemic lupus erythematodes 
ARA C: cytosine arabinoside, ATG: antithymocyte globulin, BU: busulphan, CBPT: carboplatine, CIS: cisplatine CY: cyclophosphamide, FLU: 
fludarabine, FTBI: fractionated total body irradiation, IFO: iphosphamide, MEL: melphalane, MTX: methotrexate, PRED: methylprednisolone, TH: 
thiotepa, VP: etoposide, 
A: autologous, MRD: matched related donor, MUD: matched unrelated donor, MMUD: mismatched unrelated donor  
B: bone marrow, S: stem cells, C: cord blood HSCT: hematopoietic stem cell transplantation 
1. HSCT, 2. HSCT,  1. – 4. HSCT, 5. HSCT  -: no EBV reactivation 
Table 2: Comparison of results of EBV polymerase chain reaction with EBV-associated  
     post-transplant lymphoproliferative disease 
 
 
 
EBV-genome EBV PCR    PTLD   Chi-square  sensitivity specificity     predictive value 
copies/105  in plasma present absent        test                 (%)               (%) positive negative 
PBMCs      (n=3)  (n=92) 
_______________________________________________________________________________________________________ 
 
>100,000  positive      3      0   
   P<0.001            100     100        1.00     1.00 
≤1,000  negative      0      92 
_______________________________________________________________________________________________________ 
 
EBV: Epstein-Barr virus PBMCs: peripheral blood mononuclear cells PCR: polymerase chain reaction 
PTLD: post-transplant lymphoproliferative disease 
 
Table 3: Performance of EBV polymerase chain reaction for diagnosing EBV reactivation: comparison of  
               peripheral blood mononuclear cells versus plasma as sample matrix 
 
 
 
Patients     EBV load >1,000 EBV load  ≤1,000 EBV load ≥500 EBV load <500 
EBV-genome  EBV-genome  EBV-genome EBV-genome 
copies/105  copies/105  copies/ml  copies/ml 
PBMCs (n)  PBMCs (n)  plasma (n)  plasma (n) 
____________________________________________________________________________________________ 
 
Patients with PTLD           3/3        0/3         3/3        0/3 
 
Patients at very high risk          4/4        0/4         4/4        0/4 
for PTLD → pre-emptive therapy 
 
Patients at risk for PTLD        24/24        0/24         8/24      16/24 
→ immunomodulation 
 
Patients without signs of active          0/92      92/92         0/92      92/92 
EBV infection    
____________________________________________________________________________________________ 
 
EBV: Epstein-Barr virus PBMCs: peripheral blood mononuclear cells PCR: polymerase chain reaction 
PTLD: post-transplant lymphoproliferative disease 
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Figure 1:  
Agarose gel electrophoresis of Epstein-Barr virus (EBV) nested polymerase chain 
reaction (PCR) of plasma and peripheral blood mononuclear cells (PBMCs) of patient 
8, day +84. Lane M: DNA molecular weight marker (VIII, Roche), Lane 1: DNA from 
Ramos cells (100 ng), Lane 2-11: EBV plasmid (108, 107, 106, 105, 104, 103, 102, 101, 
100, 10-1 copies/PCR), Lane 12-19: DNA from plasma (undiluted, corresponding to a 
DNA equivalent of 20 µl plasma, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128), Lane 20-37: 
DNA from PBMCs (1 µg, 500 ng, 250 ng, 125 ng, 62 ng, 31 ng, 15 ng, 8 ng, 4 ng,  
2 ng, 1 ng, 500 pg, 250 pg, 125 pg, 62 pg, 31 pg 15 pg, 8 pg), Lane 38: Control 
without DNA. Using nested EBV-specific PCR the EBV genome can still be detected 
after amplification of 10 EBV plasmid copies (lane 9). In patient 8, who developed an 
EBV-associated post-transplant lymphoproliferative disease, 16,000 EBV-genome 
copies/ml plasma and 160,000 EBV-genome copies/100,000 PBMCs could be 
detected. 
 
Figure 2A, B:  
Epstein-Barr virus (EBV) load in plasma and peripheral blood mononuclear cells 
(PBMCs). Therapeutic intervention during the course of EBV-associated post-
transplant lymphoproliferative disease (PTLD) in patient 8 (2A). Percentage of 
lymphocytes during the course of illness (2B). The high EBV load in plasma and 
PBMCs reduced dramatically after therapy. The decrease of EBV-genome copies 
was associated with a decrease of B lymphocytes and an increase of CD3+, 
CD8+/CD3+ and CD4+/CD3+ T lymphocytes. 
D L I: donor lymphocyte infusion. 
Figure 3A, B:  
Epstein-Barr virus (EBV)-genome copies in plasma and peripheral blood mono-
nuclear cells (PBMCs). Therapeutic intervention during the course of EBV-associated 
post-transplant lymphoproliferative disease (PTLD) in patient 21 (3A). Percentage of 
lymphocytes during the course of illness (3B). B cell proliferation was in line with the 
increasing EBV load. After combined therapy with cidofovir and rituximab EBV load 
reduced remarkably. The decline of EBV-genome copies and B cells was 
accompanied by a reconstitution of T-cell immunity. 
 
Figure 4: 
Epstein-Barr-virus (EBV)-genome copies and number of B lymphocytes in patient 22 
before and after pre-emptive therapy with rituximab and cidofovir. After pre-emptive 
therapy a dramatic decrease of EBV load as well as B lymphocytes occurred. 
 
